Complete response with fluorouracil and irinotecan with a BRAF<sup>V600E</sup> and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report

Zhan Wang*, Wei-Ping Dai*, Yuan-Sheng Zang
Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
*These authors contributed equally to this work

Background: Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The Southwest Oncology Group (SWOG) 1406 study evaluated the efficacy of vemurafenib in combination with irinotecan and cetuximab for simultaneous inhibition of epidermal growth factor receptor (EGFR) and BRAF in patients with BRAF<sup>V600E</sup>-mutated mCRC. Although the combination achieved higher progression-free survival (PFS) and disease control rates (DCRs), there was no complete response (CR) for the drug combination. In this case report, we report the complete recession of metastasis in a patient treated with irinotecan, cetuximab, vemurafenib, and 5-fluorouracil.

Case presentation: A 44-year-old male patient with hepatitis B was diagnosed with right-sided colon adenocarcinoma. He was treated with capecitabine plus oxaliplatin as postoperative adjuvant chemotherapy for eight cycles with a disease-free survival (DFS) of 1 year before the emergence of peritoneal and pelvic metastases. BRAF<sup>V600E</sup> mutation was positive and chemotherapy included 12 courses of 5-fluorouracil, vemurafenib, irinotecan, and cetuximab. Complete response with recession of metastases was observed.

Conclusion: The combination of fluorouracil and irinotecan with a BRAF<sup>V600E</sup> and EGFR inhibitor may have synergistic action, leading to recession of secondary metastases in patients with BRAF<sup>V600E</sup>-mutated colorectal cancer.

Keywords: mCRC, BRAF<sup>V600E</sup> mutation, fluorouracil, vemurafenib, irinotecan, cetuximab

Background
Colorectal cancer (CRC) is the third and second most frequent cancer in men and women, respectively.1 It is one of the leading causes of cancer-associated mortalities in Chinese population.2 Although histologically similar, CRCs are diverse with respect to the underlying molecular mechanism which could be explored for planning treatment strategies. Chromosomal instability, microsatellite instability, and errors in DNA repair machinery are the most frequent molecular mechanisms involved in various subgroups of CRCs.3

BRAF (v-raf murine sarcoma viral oncogene homolog B1) serine/threonine protein kinase is a downstream signaling protein in the epidermal growth factor receptor (EGFR)-activated mitogen-activated protein kinase (MAPK) pathway.4 The V600E mutation in BRAF leads to constitutive activation of MAPK pathway, and it is mostly associated with epigenetic activation of MLH1, leading to a microsatellite instability phenotype in patients with CRC.5 The RAS/RAF/MAPK pathway is downstream of...
EGFR and mutation in any gene involved in this pathway also contributes to progression of CRC. \(^6\) BRAF\(^{V600E}\) mutation defines a specific CRC subgroup with poor prognosis. \(^7,8\) BRAF and extended RAS mutations are mutually exclusive with mutation in one of the genes, signifying wild-type phenotype in the other, which might be due to the redundancy of the mutations in both the genes for CRC development. \(^9\)

A previous randomized crossover clinical trial evaluated the efficacy of irinotecan and cetuximab with and without vemurafenib in patients with BRAF\(^{V600E}\)-mutated CRC. The rationale behind the strategy is the simultaneous inhibition of EGFR and BRAF\(^{V600E}\)-mutant along with a cytotoxic agent to control metastatic CRC (mCRC). The addition of vemurafenib led to an increase in median progression-free survival (PFS) (4.4 vs 2 months) and disease control rate (DCR) (67% vs 22%). However, there was no complete response indicated by the lack of metastatic tumor mass recession. \(^10\)

In this case report, we report the successful treatment to a 44-year-old hepatitis B-positive male patient diagnosed with right-sided colon adenocarcinoma with peritoneal and pelvic metastases, with vemurafenib, irinotecan, and cetuximab along with 5-fluorouracil.

**Case presentation**

A 44-year-old male patient was diagnosed with right-sided colonic carcinoma (hepatic flexure) by electronic colonoscopy, which was confirmed by biopsy (December 22, 2016). A family enquiry revealed no incidence of CRC in first- or second-degree relatives ruling out hereditary nonpolyposis colorectal cancer (HNPCC). Furthermore, serological analysis revealed that the patient was positive for hepatitis B (HBsAg+ and HBeAg+), which led to the immediate initiation of telbivudine therapy (600 mg qd). Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 were 1.09 µg/L and 272.3 U/L, respectively. A full-body computed tomography (CT) found no metastases prompting open surgery for CRC (May 1, 2017). Surgical pathology reported poorly differentiated adenocarcinoma with sub-serosa pericolic fat invasion. One of the 16 regional lymph nodes was positive, and the resection margin was negative for cancerous tissue. The overall pathology report indicated a T3 N1 M0 stage of adenocarcinoma with probability of metastases.

The surgical adjuvant therapy included oxaliplatin, 200 mg, d1 + capecitabine, 1.5 g, d1 to d14 for eight cycles (February 9, 2017 to August 10, 2017). Evidence suggestive of metastases was not observed for almost 1 year with normal CEA and CA 19-9 levels. A positron emission tomography (PET) scan on January 3, 2018 indicated peritoneal and pelvic metastases (Figure 1B), with concomitant rise in CEA (3.15 µg/L) and CA 19-9 (886 U/L) levels. On January 12, 2018, he was switched to FOLFIRI (irinotecan, 380 mg, d1 + 5-fluorouracil, 750 mg, d1 + maintenance dose of 4.75 gm, 5-fluorouracil for 46 hours) treatment.

At the same time, the tissue sample from the initial surgery was subjected to next-generation sequencing (NGS) using Colorectal core™ panel (Burning Rock Dx, Guangzhou, China) to check for mutation in 56 different genes with therapeutic implications in targeted CRC therapy. NGS testing identified BRAF\(^{V600E}\) mutation with extended wild-type RAS. Other genetic anomalies identified by NGS included the following mutations and amplifications: BRCA2\(^{R1037V}\), ATM\(^{R337C}\), L1814F, RNF43\(^{R132}\), TP53\(^{R248W}\), Myc (copy number increase), and MCL1 (copy number increase). The clinical relevance of the mutations other than BRAF\(^{V600E}\) in CRC is not yet established.

The NGS test results were confirmed from plasma samples with circulating tumor DNA (ctDNA) in a China Food and Drug Administration (CFDA)-approved real-time PCR assay (Super-ARMS EGFR Mutation Detection Kit, Amoy Diagnostics, Xiamen, China). The real-time PCR assay targeted 17 KRAS, 13 NRAS, and 6 BRAF mutations encompassing multiple exons of the respective genes using highly sensitive probes. The only mutation observed in real-time PCR assay is the BRAF\(^{V600E}\) mutation.

With the genetic testing results, his treatment regimen also included vemurafenib and cetuximab (irinotecan, 380 mg, d1 + 5-FU, 750 mg, d1 + 5-FU, 4.75 g, d1 with maintenance for 46 hours + vemurafenib, 960 mg, qd + cetuximab, 900 mg, d1) along with FOLFIRI (folinic acid, 380 mg, d1; 5-FU, 750 mg, d1; irinotecan, 380 mg, d1) and a PET/CT scan on February 24, 2018, he was switched to FOLFIRI (irinotecan, 380 mg, d1; 5-FU, 750 mg, d1; cetuximab, 900 mg, d1) along with FOLFIRI (folinic acid, fluorouracil, and irinotecan) which was started from January 26, 2018. This treatment regimen was scheduled for 12 cycles (first cycle: irinotecan + 5-FU; second cycle: irinotecan + 5-fluorouracil + vemurafenib + cetuximab) and a PET/CT scan on February 24, 2018 (after second treatment cycle) (Figure 1C) showed recession of metastases with less sero-peritoneal invasion. A subsequent PET/CT scan on May 31, 2018 (after 10th treatment cycle) (Figure 1D) showed complete recession of metastases with no sero-peritoneal invasion. Concomitant decrease in serum CEA (2.79 µg/L) and CA 19-9 (36.92 U/L) (Figure 1E) levels was also observed. The overall clinical progression along with the treatment course is given in Figure 1A.

During the treatment course, the patient experienced grade 1/2 adverse events such as rash, diarrhea, and neutropenia, requiring no specific treatment.
Discussion and conclusion

BRAF\textsuperscript{V600E} mutation in patients with CRC is a unique molecular subtype occurring in \textasciitilde 10% of patients with mCRC and is associated with poor prognosis in the metastatic stage despite good early stage prognosis.\textsuperscript{11,12} Hence, aggressive combination chemotherapy is required to improve the survival rate in patients with BRAF\textsuperscript{V600E} mCRC.\textsuperscript{13}

The standard therapy includes surgery followed by adjuvant chemotherapy in combination with targeted therapy, which improves overall survival (OS).\textsuperscript{14} Sequential combination chemotherapy also plays an important role in CRC management, especially in mCRC.\textsuperscript{15} Cytotoxic drugs such as 5-fluourouracil combined with oxaliplatin or irinotecan are still the preferred chemotherapeutic regimen for mCRC.\textsuperscript{16} They have a synergistic effect when combined with biological agents such as EGFR and BRAF\textsuperscript{V600E}-specific inhibitors.\textsuperscript{17}

Our patient presented with metastatic CRC a year after surgical removal of right-sided colonic carcinoma and was found to have BRAF\textsuperscript{V600E} mutation by NGS. His metastases were successfully treated by simultaneous inhibition of BRAF\textsuperscript{V600E} and EGFR receptor by vemurafenib and cetuximab along with the cytotoxic drugs such as irinotecan and 5-fluorouracil.

In Southwest Oncology Group (SWOG) 1406 trial, patients with BRAF\textsuperscript{V600E}-mutant mCRC were treated with cetuximab, irinotecan, and vemurafenib. There was no indication of complete response in their study. However, the increased DFS in the vemurafenib-treated group indicated the synergistic activity of cetuximab in combination with biological agents.
with vemurafenib. Furthermore, the combination of BRAF (encorafenib) and EGFR (cetuximab) inhibitors along with MEK inhibitor (binimetinib) has been reported to be associated with an objective response rate (ORR) of 41% including a case that showed complete response in the BEACON (NCT02928224) trial.

BRAF\textsuperscript{V600E} mutation modifies the kinase domain of BRAF, leading to the monomorphic BRAF, activating the downstream signaling pathways. Vemurafenib is a small-molecule tyrosine kinase inhibitor with BRAF\textsuperscript{V600E}-specific (monomer-specific) inhibitor activity which may lead to decreased activity of the MAPK pathway. In patients with BRAF\textsuperscript{V600E}-mutated melanoma, vemurafenib monotherapy was found to be effective, which prompted its use in CRC. However, in patients with CRC, vemurafenib blocks extracellular-signal-regulated kinase (ERK) signaling, which releases upstream receptors from ERK-dependent negative feedback, resulting in increased ligand-dependent signaling that leads to subsequent activation of RAS. This generates RAF inhibitor-resistant RAF dimers. This associated rebound in ERK signaling is modest in BRAF-mutant melanomas which is not the case with CRC.

Cetuximab, which is a monoclonal antibody targeted against EGFR receptor, when combined with vemurafenib, prevents the feedback activation of RAS. It is not effective in KRAS-mutated (codon 12 and 13) CRCs, and the mutually exclusive nature of KRAS and BRAF mutations makes it a viable treatment option for BRAF-mutated CRCs. Furthermore, cetuximab has shown to revert irinotecan resistance in preclinical studies. This along with the positive results in animal experiments may have led to the initiation of the SWOG 1406 clinical trial. The treatment regimen in our patients included 5-fluorouracil along with irinotecan, cetuximab, and vemurafenib. We observed complete recession of metastases in our patients, which may be due to the additive cytotoxic effects of 5-fluorouracil. The rationale behind including 5-fluorouracil is the reported augmentation of cytotoxic activity of irinotecan in previous studies. The combination of fluorouracil with cetuximab may also result in reversion of fluorouracil resistance, which is similar to reversion of irinotecan resistance. Also, it is evident that the combination of two cytotoxic drugs with cetuximab has been effective in converting unresectable liver metastases into resectable form. Also, a post hoc analysis of the primary cancer site from the Cancer and Leukemia B and SWOG 80405 trial comparing cetuximab and bevacizumab in combination with chemotherapy revealed left-sided primary cancer to have relatively higher OS compared with right-sided primary carcinoma. Contrary to the previous publication, we observed complete recession of mCRC with right-sided primary carcinoma in our case study. Hence, we suggest that this treatment regimen could be explored as a first-line treatment for unresectable CRCs.

Furthermore, hepatitis B in patients with CRC is reported to reduce the risk of liver metastasis with simultaneous increase in extrahepatic metastasis. Furthermore, chemotherapy is reported to reactivate hepatitis B in patients with CRC, who were HBsAg-negative previously. Hence, telbivudine (600 mg qd) was administered throughout the chemotherapeutic period to obtain the optimal effects of the treatment.

The presence of only minor adverse events indicates that the drug combination is well tolerated in our case. Although we could not ascertain the long-term recurrence of mCRC and safety in our patient, the drug combination could be an option as first-line therapy for treating similar patients.

To conclude, this case report suggests that the combination of 5-fluorouracil, vemurafenib, cetuximab, and irinotecan therapy may be an option for BRAF\textsuperscript{V600E} mutations in patients with mCRC, which could be further explored in larger prospective studies to vindicate our claim.

**Ethics approval and consent to participate**

The study was approved by the institutional ethical committee and the patient signed an informed consent to participate in the study.

**Consent for publication**

Written informed consent for publication of clinical details and clinical images was obtained from the patient. A copy of the consent form is available for review by the editor of this journal.

**Acknowledgments**

The authors acknowledge Dr Kaushik Subramanian G (PhD) and Dr Anuradha Nalli (PhD) from Indegene Pvt. Ltd., Bangalore, India, for their assistance in medical writing and critical evaluation of the supporting literature while drafting this manuscript.

**Author contributions**

Zhan Wang and Wei-Ping Dai contributed to the concept and design, acquisition, analysis and interpretation of data. All authors contributed equally in data analysis, drafting and revising the article and gave final approval of the version to
be published, and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References